ESTRO 2025 - Abstract Book

S2249

Interdisciplinary – Global health

ESTRO 2025

Most respondents were non-smokers (n=25; 89%). Among smokers (11%), all reported smoking for over 15 years; two had attempted to quit, and one succeeded for more than six months using cessation aids. Stress and anxiety were common relapse triggers. While 54% (n=15) of participants could name nicotine patches as cessation aids, 14% were unable to identify any. Regarding clinical practices, 71% routinely assessed patients’ smoking habits, and nearly all (96%) advised patients to quit. However, only 43% consistently offered cessation aids to patients with smoking-related diseases, most frequently referring them to specialized consultations (75%). Collaboration with other professionals for smoking cessation was rare (25%). Moreover, 57% of participants admitted feeling inadequately prepared to educate patients about smoking cessation, and 79% expressed a need for professional training. Despite this, all participants agreed that healthcare professionals should routinely ask about smoking habits, and 82% believed professional advice could significantly improve a patient’s chances of quitting. Conclusion: This study highlights gaps in healthcare professionals’ preparedness for smoking cessation education. While the vast majority (96%) recognized the importance of routinely advising patients to quit smoking, only 43%. Notably, collaboration with other professionals for smoking cessation care was limited (25%), and over half (57%) of respondents reported feeling inadequately prepared to guide patients effectively. These findings underscore the critical need for structured training programs and multidisciplinary collaboration to empower healthcare professionals in addressing smoking habits more effectively. Digital Poster Hypofractionated Radiotherapy for Prostate Cancer: Preliminary Results from the HypoAfrica Study Abba Mallum 1 , Adedayo Joseph 2 , Solomon Kibudde 3 , Twalib Ngoma 4 , Azeezat Ajose 2 , Emmanuel Lugina 5 , Jumaa D Kisukari 5 , Awusi Kavuma 3 , Samuel Adeneye 2 , Thokozani Mkhize 1 , Adewumi Alabi 2 , Ibrahim El Hamamsi 2 , Mark Mseti 5 , Precious Akowe 2 , Andrej Studen 6 , Heng Li 7 , Joerg Lehmann 8 , Saiful Huq 9 , Stephen Avery 10 , Elizabeth Olatunji 11 , Katy Graef 12 , Saloni Patel 11 , William Swanson 13 , Wilfred Ngwa 11 , Luca Incrocci 14 1 -, Inkosi Albert Luthuli Central Hospital, Durban, South Africa. 2 -, NSIA-LUTH Cancer Center, Lagos, Nigeria. 3 -, Uganda Cancer Institute, Kampala, Uganda. 4 -, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of. 5 -, Ocean Road Cancer Institute, Dar es Salaam, Tanzania, United Republic of. 6 -, University of Ljubljana, Ljubljana, Slovenia. 7 -, Johns Hopkins University, Bethesda, USA. 8 -, Calvary Mater Newcastle, Newcastle, Australia. 9 -, UPMC Hillman Cancer Center, Pittsburgh, USA. 10 -, University of Pennsylvania, Philadelphia, USA. 11 -, Johns Hopkins University, Baltimore, USA. 12 -, BIO Ventures for Global Health, Seattle, USA. 13 -, Emory University, Atlanta, USA. 14 -, Erasmus Medical Center, Rotterdam, Netherlands Purpose/Objective: Prostate cancer (PCa) is the most common cancer among men in sub-Saharan Africa (SSA). 1 The rise of PCa in this resource-limited setting warrants the adoption of evidence-based approaches that enhance treatment accessibility. Hypofractionated radiotherapy (HFRT) substantially increases access to radiotherapy by reducing the overall cost and treatment duration for patients and decreasing the burden on limited healthcare personnel and infrastructural resources. Several randomized studies conducted in Europe and the USA have demonstrated that HFRT for PCa is non-inferior to conventional radiotherapy in terms of toxicity and treatment outcomes. 2 This study explored the feasibility of applying moderate HFRT for the treatment of localized PCa in SSA. Material/Methods: HypoAfrica is a multi-center phase 2 feasibility study that recruited men in SSA with histologically-confirmed localized PCa. Patients received an HFRT total dose of either 60Gy (low- and intermediate-risk PCa) or 62Gy (high- Keywords: Smoking Cessation 4426